Rare diseases
Investigational molecules
Locations
Efficacy and Safety of LTG-321 Compared with Placebo in Patients with Osteoarthritis of the Knee
DenmarkBempedoic acid in drug combination for patients with coronary artery disease without prior cardiovascular events
GermanyStudy of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer
FranceA Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis
FranceSafety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial
GermanyLong‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)
AustriaEpcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study
GermanyEffect of dapagliflozin and semaglutide on heart insulin resistance in type 2 diabetes patients
SpainTacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients
The NetherlandsSwitch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer
GermanyLong‑Term Safety Follow‑up of Ornithine Transcarbamylase Deficiency Patients Treated with ECUR‑506D and ECUR‑506A
FranceEfficacy of intravenous prasinezumab versus placebo in Parkinson's disease patients with severe GBA mutation: a 104‑week randomized double‑blind study
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
